Sensorion SA (ALSEN)
Euronext
Closed
Oct 9, 2026
Day's Range
5.7552 wk Range
5.75Overview - ALSEN - Sensorion SA
Key Statistics
Valuation
Enterprise Value
-11.92M
P/E (Trailing)
‪-73.93‬
P/E (Forward)
‪-4.76‬
PEG Ratio
‪-4.76‬
Price / Sales (TTM)
‪11.92‬
Price / Book
‪0.96‬
EV / EBITDA
‪0.34‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-802.92%‬
Return on Assets
‪-25.38%‬
Return on Equity
‪-49.26%‬
Ownership
Shares Outstanding
300.34M
Float
6.01M
Held by Insiders
‪34.76%‬
Held by Institutions
‪35.50%‬
Price stats
Beta
‪0.41‬
50-Day Avg
‪12.72‬
200-Day Avg
‪16.63‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
5 analysts
Average price target
‪€ 1.14‬Market Cap - ALSEN - Sensorion SA
Peers - ALSEN - Sensorion SA
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - ALSEN - Sensorion SA
About
Sensorion SA is a clinical-stage biotechnology company focused on developing therapies for inner ear disorders and hearing loss. Sensorion SA’s current portfolio centers on drug candidates and gene therapy programs designed to restore, treat, and prevent conditions such as sudden sensorineural hearing loss, cochlear…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
